<DOC>
	<DOC>NCT00315211</DOC>
	<brief_summary>The purposes of this study are: - To determine the overall response rate of patients treated with at least 2 cycles of this regimen. - To determine the feasibility and toxicity of the combination of topotecan and docetaxel.</brief_summary>
	<brief_title>Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mediastinal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Recurred greater than 90 days after initial treatment At least 1 measurable lesion Only 1 prior chemotherapy Must be over 18 years of age ECOG performance status of 0 2 Adequate hematologic, renal, and hepatic function No prior use of topotecan, docetaxel, or irinotecan No symptomatic brain metastases History of cardiac arrhythmias, congestive heart failure, stroke, or embolic events No prior investigational agents within 1 month prior Lung cancer of mixed histology Known uncontrolled seizure disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Small Cell Lung Cancer Recurrent</keyword>
</DOC>